News | September 03, 2025
Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
Facility designed to advance the next generation of imaging systems
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Subscribe To Our Newsletter & Stay Updated
